In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of the National Cancer Institute

• Publication date

  1997-02-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/89.4.293PMID 9048833
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular characterization of defective antigen processing in human prostate cancer.

  1995cited by this paper
• A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

  1995influential reference
• Serial triggering of many T-cell receptors by a few peptide–MHC complexes

  1995cited by this paper
• Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21

  1995cited by this paper
• Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

  1995cited by this paper
• Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.

  1995cited by this paper
• Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.

  1995cited by this paper
• Sequence motifs of human her-2 protooncogene important for Peptide binding to hla-A2.

  1994cited by this paper
• Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

  1994cited by this paper
• Prostate cancer kills: strategy to reduce deaths.

  1994cited by this paper
• In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.

  1994cited by this paper
• Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins.

  1994cited by this paper
• Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

  1994cited by this paper
• Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones.

  1994cited by this paper
• In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

  1993cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• Intracellular transport of class I MHC molecules in antigen processing mutant cell lines.

  1993cited by this paper
• Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2.

  1993cited by this paper
• Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

  1993cited by this paper
• Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.

  1993cited by this paper
• Toward a genetic analysis of tumor rejection antigens.

  1992cited by this paper
• T‐cell recognition of oncogene products: A new strategy for immunotherapy

  1992cited by this paper
• Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor

  1992cited by this paper
• Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.

  1992cited by this paper
• Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.

  1992cited by this paper
• MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.

  1991cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

  1991cited by this paper
• Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins

  1991cited by this paper
• Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

  1991cited by this paper
• Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction

  1991cited by this paper
• Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins

  1991cited by this paper
• Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma.

  1990cited by this paper
• The minimal number of class II MHC-antigen complexes needed for T cell activation.

  1990cited by this paper
• Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation

  1990cited by this paper
• The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

  1989cited by this paper
• Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens

  1989cited by this paper
• NK susceptibility varies inversely with target cell class I HLA antigen expression.

  1987cited by this paper
• Prostate antigen: a marker for human prostate epithelial cells.

  1981cited by this paper
• A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field.

  1968cited by this paper
• “ Role of HLA-A Motifs in Identification of Potential CTL Epitopes Inhuman Papillomavirus Type 16 E 6 and E 7 Proteins ”

  year unknowncited by this paper

• mRNA vaccines for prostate cancer: A novel promising immunotherapy.

  2025cites this paper
• Assessment of immunotoxicity in the 21st century: where we are and what we need to replace animals

  2025cites this paper
• Nanomedicine in Immunotherapy for Non‐Small Cell Lung Cancer: Applications and Perspectives

  2025cites this paper
• TCR-based therapy directed against kallikrein-related peptidase 4 is safe and effective against prostate cancer.

  2025cites this paper
• Immuno-Oncology at the Crossroads: Confronting Challenges in the Quest for Effective Cancer Therapies

  2025cites this paper
• An In Vitro Test Battery using Human Whole Blood for Immunotoxicity Hazard Identification: Proof of Concept Studies with Dexamethasone and Benzo(a)pyrene.

  2025cites this paper
• The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines

  2024cites this paper
• Cancer Vaccines: A Novel Revolutionized Approach to Cancer Therapy

  2024cites this paper
• "Innovations in Cancer Immunotherapy: A Comprehensive Overview of Recent Breakthroughs and Future Directions".

  2024cites this paper
• New approaches and prospects of immunotherapy and gene therapy for prostate cancer

  2024cites this paper
• Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer

  2024cites this paper
• Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management.

  2024cites this paper
• T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics.

  2024cites this paper
• Vaccines as treatments for prostate cancer

  2023cites this paper
• Cancer Vaccines in the Immunotherapy Era: Promise and Potential

  2023cites this paper
• Peptide-based vaccine for cancer therapies

  2023cites this paper
• Peptide-Based Therapeutics in Cancer Therapy

  2023cites this paper
• Co-transient expression of PSA-Fc and PAP-Fc fusion protein in plant as prostate cancer vaccine candidates and immune responses in mice

  2023cites this paper
• Peptides for Vaccine Development

  2022cites this paper
• Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application.

  2022cites this paper
• Development of Peptide-Based Vaccines for Cancer

  2022cites this paper
• Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers

  2022cites this paper
• Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

  2022cites this paper
• Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).

  2021cites this paper
• Development of neoantigens: from identification in cancer cells to application in cancer vaccines

  2021cites this paper
• A New Generation of Vaccines in the Age of Immunotherapy

  2021cites this paper
• MUCIN 1 in Prostate Cancer

  2021cites this paper
• Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics

  2021cites this paper
• Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment

  2021cites this paper
• The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review

  2021cites this paper
• Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

  2020cites this paper
• Selecting Target Antigens for Cancer Vaccine Development

  2020cites this paper
• Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

  2020cites this paper
• Bioinformatic Identification of a Breast‐Specific Transcript Profile

  2020cites this paper
• From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy.

  2019cites this paper
• Turning the corner on therapeutic cancer vaccines

  2019cites this paper
• The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review

  2019cites this paper
• New Approaches on Cancer Immunotherapy.

  2019cites this paper
• Genetically engineered T cells for cancer immunotherapy

  2019cites this paper
• Intracellular targets as source for cleaner targets for the treatment of solid tumors.

  2019cites this paper
• Immunotherapy for Treatment of Cancer

  2018cites this paper
• Immune-based therapies for metastatic prostate cancer: an update.

  2018cites this paper
• Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

  2018cites this paper
• Caractérisation topologique d'interactions non-covalentes inter- et intramoléculaires

  2017cites this paper
• [Immunotherapy: Activation of a system not a pathway].

  2017cites this paper
• Immunothérapie : après le focus sur les voies de signalisation, l’activation d’un système

  2017cites this paper
• Prostate cancer immunotherapy: where are we and where are we going?

  2017cites this paper
• Advancements in Tumor Immunotherapy and Cancer Vaccines 38 preclinical studies

  2017influential citation
• Opportunities and challenges for TCR mimic antibodies in cancer therapy

  2016cites this paper
• Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse

  2016cites this paper
• Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.

  2016cites this paper
• T cell receptor mimic antibodies for cancer therapy

  2016cites this paper
• Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

  2016cites this paper
• Immunotherapy of Prostate Carcinoma with biodegradable PLGA Microspheres

  2015cites this paper
• Insights on Peptide Vaccines in Cancer Immunotherapy

  2015cites this paper
• Human Tumor Antigens and Cancer Immunotherapy

  2015cites this paper
• Apprêtement non conventionnel de peptides antigéniques : production d’antigènes tumoraux par épissage inverse dans le protéasome ou par des protéases distinctes du protéasome

  2015cites this paper
• PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope–Modified DNA Vaccine Immunization

  2015cites this paper
• Antigen-specific vaccines for cancer treatment

  2014cites this paper
• Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy

  2014cites this paper
• Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens

  2014cites this paper
• Innate and Adaptive Immune Responses to Cancer

  2014cites this paper
• CpG-DNA – a potential adjuvant in prostate cancer immunotherapy

  2014cites this paper
• Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

  2014cites this paper
• Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• TRICOM Poxviral-Based Vaccines for the Treatment of Cancer

  2014cites this paper
• Tumor-Specific Immune Responses and Present Their Antigens to Elicit Dendritic Cells Capture Killed Tumor Cells

  2013influential citation
• Therapeutic cancer vaccines: past, present, and future.

  2013cites this paper
• Generation of Potent Cytotoxic T Lymphocytes Against Castration‐Resistant Prostate Cancer Cells by Dendritic Cells Loaded With Dying Allogeneic Prostate Cancer Cells

  2013cites this paper
• Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma

  2013cites this paper
• Safety analysis of TCR gene-modified T cells

  2012cites this paper
• A Novel HLA-A2–restricted CTL Epitope of Tumor-associated Antigen L6 can Inhibit Tumor Growth In Vivo

  2012cites this paper
• Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer.

  2012cites this paper
• Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

  2012cites this paper
• Challenges to Prostate Cancer Immunotherapy

  2012influential citation
• Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients

  2012cites this paper
• Prostate cancer vaccines in clinical trials

  2012cites this paper
• Prevalence of possible immune resistance mechanisms of acute leukemias within the context of vaccination strategies using the Wilms tumor gene-1 (WT1)

  2012cites this paper
• Immunotherapeutic approaches targeting prostate cancer and its microenvironment

  2012cites this paper
• Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer

  2012cites this paper
• Type‐1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8+ T cells against prostate cancer cells and defined prostate cancer‐specific epitopes

  2011cites this paper
• Prostatakarzinom

  2011cites this paper
• Isolierung und Charakterisierung tumorassoziierter MHC- Klasse-I- und Klasse-II-Peptide aus soliden Nierenzell- und Cholangiozellulären Karzinomen

  2011cites this paper
• Optimised electroporation mediated DNA vaccination for treatment of prostate cancer

  2010cites this paper
• Charakterisierung des Bax Inhibitor-1 Peptides als neues tumorassoziiertes T-Zellepitop

  2010cites this paper
• Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic mice

  2010cites this paper
• Translating Tumor Antigens into Cancer Vaccines

  2010cites this paper
• Dendritic Cell-Based Immunotherapy for Prostate Cancer

  2010cites this paper
• The Prostate 70 : 1002 ^ 1011 ( 2010 ) AndrogenAblationAugmentsHuman HLA 2 . 1-RestrictedT cell Responses to PSASelf-Antigen inTransgenicMice

  2010cites this paper
• Defining novel targets for immunotheraphy of human cancer

  2010cites this paper
• Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design

  2010cites this paper
• The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.

  2010cites this paper
• ON IMMUNOTHERAPY AGAINST PROSTATE CANCER

  2010cites this paper
• Molecular and cellular expression of novel genes associated with breast cancer

  2009cites this paper
• Part One Tumor-associated Antigens ( TAAs ) : Subclasses of TAAs

  2009cites this paper
• Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

  2009cites this paper
• ÉVALUATION DES PROTEINES MIDKINE ET SURVIVINE SUREXPRIMEES DANS LES CELLULES TUMORALES COMME CIBLES DE L'IMMUNITE CELLULAIRE ANTI-TUMORALE

  2009cites this paper
• Prostate autoimmunity: from experimental models to clinical counterparts

  2009cites this paper
• A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.

  2009cites this paper